The allogeneic dilemma


The place of allogeneic SCT in the management of multiple myeloma remains controversial. Although it may induce long-term clinical and molecular remissions, the very high transplant-related toxicity after a myeloablative preparative regimen has limited its role to younger patients as first-line treatment option. Even with this limited indication, toxic… (More)
DOI: 10.1038/sj.bmt.1705810


2 Figures and Tables

Cite this paper

@article{Harousseau2007TheAD, title={The allogeneic dilemma}, author={J M Harousseau}, journal={Bone Marrow Transplantation}, year={2007}, volume={40}, pages={1123-1128} }